Allergan Inc. (AGN)

AGN (NYSE:Drugs)
pos +2.46
Today's Range: 129.20 - 134.41 | AGN Avg Daily Volume: 2,910,900
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 5,091,091
YTD Performance: 20.56%
Open: $130.38
Previous Close: $131.46
52 Week Range: $81.33 - $134.41
Oustanding Shares: 298,467,649
Market Cap: 39,320,867,037
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 9 10 11
Moderate Buy 0 0 0 0
Hold 7 7 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.82 1.88 1.89 1.84
Latest Dividend: 0.05
Latest Dividend Yield: 0.15%
Dividend Ex-Date: 02/26/14
Price Earnings Ratio: 31.24
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
31.24 40.60 29.01
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.46% 18.53% 73.92%
Revenue 8.50 0.28 0.09
Net Income -10.30 258.69 5.26
EPS -9.80 0.00 0.00
Earnings for AGN:
Revenue 6.30B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $1.12 $1.35 $5.45 $6.17
Number of Analysts 12 12 15 14
High Estimate $1.15 $1.41 $5.50 $6.30
Low Estimate $1.09 $1.24 $5.38 $5.78
Prior Year $0.98 $1.22 $4.77 $5.45
Growth Rate (Year over Year) 14.03% 10.38% 14.24% 13.22%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Some unexpected stocks and sectors have climbed the market's wall of worry.
Feb 11, 2014 | 7:59 AM EST
Shares of AGN now seen reaching $140, according to Credit Suisse. Estimates also increased, as the company has multiple growth drivers....
Believe in CEOs with a history of winning seasons.
Dec 24, 2013 | 7:23 AM EST
AGN was upgraded from Market Perform to Outperform, Wells Fargo said. New patents will likely protect Restasis. 
Dec 20, 2013 | 8:05 AM EST
AGN raised its numbers, UBS said. Driven by new patents for Restasis. $116 price target and Buy rating. 
Dec 12, 2013 | 7:53 AM EST
Shares of AGN now seen reaching $112, according to Credit Suisse. Estimates also increased, as management is turning the business aroun...
Newmont Mining is attractive on several valuation measures
Jul 11, 2013 | 7:41 AM EDT
Shares of AGN now seen reaching $100, according to Lazard Capital Markets Restasis could face increased competition from generics. Buy ...
Jun 25, 2013 | 8:04 AM EDT
AGN was downgraded from Outperform to Market Perform, Wells Fargo said. Restasis will likely soon face generic competition.
Jun 24, 2013 | 8:00 AM EDT
AGN's future earnings estimates have been lowered as concern mounts over generic production of the firm's second largest drug, said Lee...

Columnist Conversations

There were nice reversal-type candles on the weekly charts of the major indices. The DOW and the S&P forme...
A number of stocks on my watch lists are attempting to form positive candles a key support levels. I noted th...
While last week was a day to pull the plug and contemplate where the market was headed, I waited for some conf...
Shares of TSLA have formed multiple hammer candles at a key level of support defined by: the September head an...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.